Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/sti.2011.d1906rep | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia.
Schizophr Res Cogn
June 2025
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
Unlabelled: Despite significant patient burden, there are no approved pharmacotherapies to treat symptoms of cognitive impairment associated with schizophrenia (CIAS). This double-blind, placebo-controlled, parallel-group Phase II trial assessed the efficacy and safety of pharmacological augmentation of at-home computerized cognitive training (CCT) with iclepertin (BI 425809, a glycine transporter-1 inhibitor). Participants with schizophrenia (aged 18-50 years) on stable antipsychotic therapy, who were compliant with CCT during the run-in period, were enrolled.
View Article and Find Full Text PDFCharacteristics Associated with Engagement in the Early Detection Cascade of Care for Psychosis at a College Counseling Center.
Community Ment Health J
January 2025
Health Sciences Center, Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USA.
Using the Cascade of Care framework, we explored the demographic and clinical characteristics of students at six stages in an early psychosis detection program at a college counseling center, with a focus on the transition between stages with the highest disengagement. We detailed and compared the demographic and clinical characteristics of those who (1) completed the Prodromal Questionnaire-Brief (PQ-B, N = 1588); (2) met the PQ-B cutoff score (n = 486); (3) were referred for secondary phone screening (n = 404); (4) completed secondary phone screening (n = 198); (5) completed a Coordinated Specialty Care (CSC) eligibility assessment (n = 51); and (6) were enrolled in CSC (n = 21). Education level and gender identity were associated with engagement at multiple stages of the early detection cascade.
View Article and Find Full Text PDFCommunications needs of family caregivers of geriatric unit residents at end-of-life.
Gerontologist
January 2025
Department of Health Promotion, School of Public Health, Faculty of Medical and Health Sciences, Tel Aviv University, Israel.
Background And Objective: There is a dearth of literature regarding the communication needs of family caregivers of institutionalized older adults and the degree to which these needs are fulfilled. This study aimed to clarify those needs regarding communication with staff in geriatric facilities during older non-communicative residents' end-of-life.
Research Design And Methods: Personal interviews were conducted with 135 family caregivers from two geriatric medical centers and two nursing homes in Israel.
Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.
Psychiatry Res
December 2024
Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of Randomized Placebo-Controlled Clinical Trials (RCTs) registered with PROSPERO was conducted.
View Article and Find Full Text PDFMental Health Services for Serious Mental Illness: Scoping Review of Randomised Controlled Trials.
Nurs Open
January 2025
Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Aims: This review aims to classify the evidence from randomised controlled trials (RCTs) on mental health services (MHS) for people with serious mental illness (SMI) available in the Cochrane Schizophrenia Group's (CSzG) specialised register.
Design: Scoping review.
Methods: We retrieved and screened RCTs of service-level interventions considering non-pharmacological approaches for mental healthcare of the CSzG register.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!